RE: Change of preliminary results date12 Aug 2022 08:19
Update on CD4 sale proceeds
Following the finalisation of the CD4 inventory valuation as at 31 July 2022, there has been an upward revision to the estimated sale proceeds from the originally stated aggregate cash consideration of up to GBP6.1m, before costs, to up to GBP6.3m. This results in an increase in the upfront cash payment due to the Company from GBP1,100,000 to GBP1,315,000, of which GBP463,000 has already been received. The balance is due to be received within the next 10 business days.